An ongoing phase III clinical trial (NCT02062489) is currently evaluating the effectiveness of adjuvant tamoxifen therapy in ERα/PR-negative, ERβ-positive operable breast cancer patients [37]. Here, ESR2 is linked to breast carcinoma.